Based in the US, Crinetics Pharmaceuticals is involved in the development of treatments for rare endocrine disorders and endocrine-related cancers.
The company plans to use funds for financing the development of its oral non-peptide somatostatin agonist CRN00808 and to develop additional new targeted therapeutics.
Australian biopharmaceutical company Immuron Ltd has issued 13 million shares priced at A$0.39 ($0.31) a share in a private placement to raise A$5.13m ($4.04m).
A US institutional investment fund will subscribe to the placement.
The company plans to use proceeds to fund ongoing clinical programmes, to support marketing initiatives related to its Travelan product, and for working capital needs.
The company has appointed Joseph Gunnar & CO LLC and HC Wainwright & Co as joint placement agents for the transaction.
US-based biopharmaceutical company Puretech Health plc has issued 45 million shares priced at £1.60 ($2.215) a share in a private placement to raise £72m ($100m).
Institutional investors have subscribed to the placement.
The company plans to use funds towards the development of growth-stage affiliates targeting the brain-immune-gut axis.
Aquinox Pharmaceuticals Inc has filed a shelf registration statement with the US Securities and Exchange Commission (SEC ) to raise $250m through a public offering of securities.
The Canadian pharmaceutical company plans to use proceeds towards the research and development of its product candidates, and for general corporate purposes.
The company has appointed Cooley LLP as legal advisor for the transaction.
Prevail Therapeutics has received $75m in a Series A funding round, which involved participation from OrbiMed, Pontifax Fund , RA Capital Management, EcoR1 Capital , Omega Funds, BVF Partners , Boxer Capital , Adage Capital Management and Alexandria Venture Investments .
The US-based biotech company has also obtained seed funding from OrbiMed and the Silverstein Foundation.
The company plans to use the funds towards the development of gene therapies for neurodegenerative disorders including Parkinson’s disease.
The US-based artificial intelligence start-up will use funding for the development of its drug research technology AtomNet, which uses algorithms to predict the potential of new drugs, reducing cost, and risks associated with development.